Gareen, Ilana

Ilana F Gareen

Associate Professor of Epidemiology (Research)

Overview

Dr. Gareen has been a member of the faculty of Brown’s Center for Statistical Sciences since 1999. She is an epidemiologist with over a decade of experience in the collaborative design and conduct of studies of diagnostic imaging technologies. Her research focuses on patient outcomes associated with diagnostic imaging technologies, including the impact of imaging on patient health, patient quality of life, and medical care utilization. One of the patient outcomes of particular interest to Dr. Gareen is the impact of significant incidental findings (SIFs) on patient health and medical care utilization. As Co-Chair for the American College of Radiology Imaging Network (ACRIN) 6654 National Lung Screening Trial (NLST), Dr. Gareen was a key member of the NLST Executive Committee responsible for day-to-day operation of the trial, as well as for publication and dissemination of the primary trial results. Dr. Gareen was also responsible for overseeing the collection of information on outcomes and health care utilization from the medical records and the endpoint verification process in the ACRIN arm of the trial. As a co-investigator on the Grand Opportunity grant Comparative Effectiveness of Advanced Imaging in Cancer, Dr. Gareen is examining the effect of SIFs on Medicare costs following lung screening. She has also provided methodologic leadership for the design, development, and implementation of a study examining the incidence and significance of extracolonic findings (SIFs) in the National CT Colonography Trial.

Brown Affiliations

Epidemiology

Research Areas

Publications Visualize it

Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC. "Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer." JAMA Network Open, vol. 7, no. 1, 2024, pp. e2350844.

Full Text PubMed

Rabinovici GD, Carrillo MC, Apgar C, Gareen IF, Gutman R, Hanna L, Hillner BE, March A, Romanoff J, Siegel BA, Smith K, Song Y, Weber C, Whitmer RA, Gatsonis C. "Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia." JAMA neurology, vol. 80, no. 11, 2023, pp. 1166-1173.

Full Text PubMed

Streck JM, Lee JW, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Carlos RC, Kumar S, Mayer IA, Saba NF, Fenske TS, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. "Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials." Cancer Epidemiology Biomarkers & Prevention, vol. 32, no. 11, 2023, pp. 1552-1557.

Full Text PubMed

Gareen IF, Hoffman RM, Tailor TD. "Separating Actionable From Incidental Findings-Imperative for Meaningful Clinical Outcomes-Reply." JAMA Internal Medicine, vol. 183, no. 10, 2023, pp. 1176-1177.

Full Text PubMed

Gareen IF, Gutman R, Sicks J, Tailor TD, Hoffman RM, Trivedi AN, Flores E, Underwood E, Cochancela J, Chiles C. "Significant Incidental Findings in the National Lung Screening Trial." JAMA Internal Medicine, vol. 183, no. 7, 2023, pp. 677-684.

Full Text PubMed

Lin MY, Liu T, Gatsonis C, Sicks JD, Shih S, Carlos RC, Gareen IF. "Utilization of Diagnostic Procedures After Lung Cancer Screening in the National Lung Screening Trial." Journal of the American College of Radiology : JACR, vol. 20, no. 10, 2023, pp. 1022-1030.

Full Text PubMed

Sadigh G, Gray RJ, Sparano JA, Yanez B, Garcia SF, Timsina LR, Obeng-Gyasi S, Gareen I, Sledge GW, Whelan TJ, Cella D, Wagner LI, Carlos RC. "Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial." JAMA Oncology, vol. 8, no. 4, 2022, pp. 579-586.

Full Text PubMed

Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI. "Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy." Cancer, vol. 128, no. 3, 2022, pp. 536-546.

Full Text PubMed

Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, Rahbar H, Sung JS, Jacobs C, Harvey JA, Nicholson MH, Ward RC, Holt J, Prather A, Miller KD, Schnall MD, Kuhl CK. "Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening." JAMA, vol. 323, no. 8, 2020, pp. 746-756.

Full Text PubMed

Black WC, Chiles C, Church TR, Gareen IF, Gierada DS, Mahon I, Miller EA, Pinsky PF, Sicks JD. "Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team 1." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019.

Full Text PubMed

Corl KA, Prodromou M, Merchant RC, Gareen I, Marks S, Banerjee D, Amass T, Abbasi A, Delcompare C, Palmisciano A, Aliotta J, Jay G, Levy MM. "The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study." Critical care medicine, vol. 47, no. 7, 2019, pp. 951-959.

Full Text PubMed

Gareen IF, Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Siegel BA. "Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry." Journal of Nuclear Medicine, vol. 59, no. 3, 2018, pp. 427-433.

Full Text PubMed

Gareen, Ilana F., Black, William C., Tosteson, Tor D., Wang, Qianfei, D. Sicks, JoRean, Tosteson, Anna N.A. "Medical Care Costs were Similar Across the Low-Dose Computed Tomography and Chest X-ray Arms of the National Lung Screening Trial (NLST) Despite Different Rates of Significant Incidental Findings." Medical Care, 2018, pp. 1.

Full Text PubMed

Gareen IF, Black WC, Tosteson TD, Wang Q, Sicks JD, Tosteson ANA. "Medical Care Costs were Similar Across the Low-Dose Computed Tomography and Chest X-ray Arms of the National Lung Screening Trial (NLST) Despite Different Rates of Significant Incidental Findings." Medical Care, vol. 56, no. 5, 2018, pp. 403-409.

Full Text PubMed

Hillner BE, Hanna L, Makineni R, Duan F, Shields AF, Subramaniam RM, Gareen I, Siegel BA. "Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry." Journal of Nuclear Medicine, vol. 59, no. 3, 2017, pp. 421-426.

Full Text PubMed

Trosman JR, Carlos RC, Simon MA, Madden DL, Gradishar WJ, Benson AB 3rd, Rapkin BD, Weiss ES, Gareen IF, Wagner LI, Khan SA, Bunce MM, Small A, Weldon CB. "Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery." Journal of Oncology Practice, vol. 12, no. 11, 2016, pp. 1101-1113.

Full Text PubMed

Marcus PM, Doria-Rose VP, Gareen IF, Brewer B, Clingan K, Keating K, Rosenbaum J, Rozjabek HM, Rathmell J, Sicks J, Miller AB. "Did death certificates and a death review process agree on lung cancer cause of death in the National Lung Screening Trial?." Clinical Trials, vol. 13, no. 4, 2016, pp. 434-8.

Full Text PubMed

Kumar P, Gareen IF, Lathan C, Sicks JD, Perez GK, Hyland KA, Park ER. "Racial Differences in Tobacco Cessation and Treatment Usage After Lung Screening: An Examination of the National Lung Screening Trial." The oncologist, vol. 21, no. 1, 2016, pp. 40-9.

Full Text PubMed

Stillman AE, Gatsonis C, Lima JA, Black WC, Cormack J, Gareen I, Hoffmann U, Liu T, Mavromatis K, Schnall MD, Udelson JE, Woodard PK. "Rationale and design of the Randomized Evaluation of patients with Stable angina Comparing Utilization of noninvasive Examinations (RESCUE) trial." American Heart Journal, vol. 179, 2016, pp. 19-28.

Full Text PubMed

Gareen IF, Siewert B, Vanness DJ, Herman B, Johnson CD, Gatsonis C. "Patient willingness for repeat screening and preference for CT colonography and optical colonoscopy in ACRIN 6664: the National CT Colonography trial." Patient preference and adherence, vol. 9, 2015, pp. 1043-51.

Full Text PubMed

Park ER, Gareen IF, Japuntich S, Lennes I, Hyland K, DeMello S, Sicks JD, Rigotti NA. "Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial." JAMA Internal Medicine, vol. 175, no. 9, 2015, pp. 1509-16.

Full Text PubMed

Clark, Melissa A., Gorelick, Jeremy J., Sicks, JoRean D., Park, Elyse R., Graham, Amanda L., Abrams, David B., Gareen, Ilana F. "The Relations between False Positive and Negative Screens and Smoking Cessation and Relapse in the National Lung Cancer Screening Trial: Implications for Public Health." Nicotine & Tobacco Research, 2015, pp. ntv037.

Full Text PubMed

Park ER, Streck JM, Gareen IF, Ostroff JS, Hyland KA, Rigotti NA, Pajolek H, Nichter M. "A qualitative study of lung cancer risk perceptions and smoking beliefs among national lung screening trial participants." Nicotine & Tobacco Research, vol. 16, no. 2, 2014, pp. 166-73.

Full Text PubMed

Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, Gatsonis C, National Lung Screening Trial Research Team. "Cost-effectiveness of CT screening in the National Lung Screening Trial." New England Journal of Medicine, vol. 371, no. 19, 2014, pp. 1793-802.

Full Text PubMed

Gareen IF, Duan F, Greco EM, Snyder BS, Boiselle PM, Park ER, Fryback D, Gatsonis C. "Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial." Cancer, vol. 120, no. 21, 2014, pp. 3401-9.

Full Text PubMed

Park ER, Gareen IF, Jain A, Ostroff JS, Duan F, Sicks JD, Rakowski W, Diefenbach M, Rigotti NA. "Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up." Cancer, vol. 119, no. 7, 2013, pp. 1306-13.

Full Text PubMed

Gareen IF, Sicks JD, Jain AA, Moline D, Coffman-Kadish N. "Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: the model used by the American College of Radiology arm of the National Lung Screening Trial." Contemporary Clinical Trials, vol. 34, no. 1, 2013, pp. 36-44.

Full Text PubMed

National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. "Results of initial low-dose computed tomographic screening for lung cancer." New England Journal of Medicine, vol. 368, no. 21, 2013, pp. 1980-91.

Full Text PubMed

Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J, National Lung Screening Trial Research Team. "Results of the two incidence screenings in the National Lung Screening Trial." New England Journal of Medicine, vol. 369, no. 10, 2013, pp. 920-31.

Full Text PubMed

Hillner BE, Siegel BA, Hanna L, Shields AF, Duan F, Gareen IF, Quinn B, Coleman RE. "Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts." Journal of Nuclear Medicine, vol. 53, no. 5, 2012, pp. 831-7.

Full Text PubMed

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. "Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations." Radiology, vol. 261, no. 2, 2011, pp. 487-98.

Full Text PubMed

Stillman AE, Woodard PK, RESCUE Investigators. "Consequence of overuse of invasive coronary angiography." Arch Intern Med, vol. 171, no. 7, 2011, pp. 709; author reply 709-10.

Full Text PubMed

Hillner BE, Siegel BA, Shields AF, Duan F, Gareen IF, Hanna L, Coleman RE. "Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry." Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, vol. 13, no. 1, 2011, pp. 161-5.

Full Text PubMed

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. "Reduced lung-cancer mortality with low-dose computed tomographic screening." New England Journal of Medicine, vol. 365, no. 5, 2011, pp. 395-409.

Full Text PubMed

Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. "The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death." Contemporary Clinical Trials, vol. 32, no. 6, 2011, pp. 834-40.

Full Text PubMed

National Lung Screening Trial Research Team., Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. "The National Lung Screening Trial: overview and study design." Radiology, vol. 258, no. 1, 2011, pp. 243-53.

Full Text PubMed

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, Gareen IF, Lynch DA, Marcus PM, Pinsky PF. "Baseline characteristics of participants in the randomized national lung screening trial." JNCI Journal of the National Cancer Institute, vol. 102, no. 23, 2010, pp. 1771-9.

Full Text PubMed

Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. "National Institutes of Health consensus development conference statement: management of hepatitis B." Hepatology, vol. 49, no. 5 Suppl, 2009, pp. S4-S12.

Full Text PubMed

Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. "National Institutes of Health Consensus Development Conference Statement: management of hepatitis B." Annals of Internal Medicine, vol. 150, no. 2, 2009, pp. 104-10.

Full Text PubMed

Park ER, Ostroff JS, Rakowski W, Gareen IF, Diefenbach MA, Feibelmann S, Rigotti NA. "Risk perceptions among participants undergoing lung cancer screening: baseline results from the National Lung Screening Trial." Annals of Behavioral Medicine, vol. 37, no. 3, 2009, pp. 268-79.

Full Text PubMed

Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hanna L, Stine SH, Coleman RE. "The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry." Cancer, vol. 115, no. 2, 2009, pp. 410-8.

Full Text PubMed

Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE. "Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry." Journal of Clinical Oncology, vol. 26, no. 13, 2008, pp. 2155-61.

Full Text PubMed

Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Sorrell MF, Strader DB, Trotter HT. "NIH consensus development statement on management of hepatitis B." NIH consensus and state-of-the-science statements, vol. 25, no. 2, 2008, pp. 1-29.

PubMed

Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE. "Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry." Journal of Nuclear Medicine, vol. 49, no. 12, 2008, pp. 1928-35.

Full Text PubMed

Gareen IF. "Noncompliance in cancer screening trials." Clinical Trials, vol. 4, no. 4, 2007, pp. 341-9.

Full Text PubMed

Hillner BE, Liu D, Coleman RE, Shields AF, Gareen IF, Hanna L, Stine SH, Siegel BA. "The National Oncologic PET Registry (NOPR): design and analysis plan." Journal of Nuclear Medicine, vol. 48, no. 11, 2007, pp. 1901-8.

Full Text PubMed

Lazarus E, Mainiero MB, Gareen IF. "Effect of referring physician specialty and practice type on referral for image-guided breast biopsy." Journal of the American College of Radiology : JACR, vol. 2, no. 6, 2005, pp. 488-93.

Full Text PubMed

Gareen IF, Morgenstern H, Greenland S, Gifford DS. "Explaining the association of maternal age with Cesarean delivery for nulliparous and parous women." American Journal of Kidney Diseases, vol. 56, no. 11, 2003, pp. 1100-10.

Full Text PubMed

Gareen IF. "Intrauterine devices and pelvic inflammatory disease." Current women's health reports, vol. 3, no. 4, 2003, pp. 280-7.

PubMed

Gareen IF, Gatsonis C. "Primer on multiple regression models for diagnostic imaging research." Radiology, vol. 229, no. 2, 2003, pp. 305-10.

Full Text PubMed

Mayo-Smith WW, Rhea JT, Smith WJ, Cobb CM, Gareen IF, Dorfman GS. "Transportable versus fixed platform CT scanners: comparison of costs." Radiology, vol. 226, no. 1, 2003, pp. 63-8.

Full Text PubMed

Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, Reiss PT, Medeiros AA. "Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae." Clinical Infectious Diseases, vol. 35, no. 5, 2002, pp. 556-64.

Full Text PubMed

Mainiero MB, Gareen IF, Bird CE, Smith W, Cobb C, Schepps B. "Preferential use of sonographically guided biopsy to minimize patient discomfort and procedure time in a percutaneous image-guided breast biopsy program." Journal of Ultrasound in Medicine, vol. 21, no. 11, 2002, pp. 1221-6.

Full Text PubMed

Gareen IF, Greenland S, Morgenstern H. "Intrauterine devices and pelvic inflammatory disease: meta-analyses of published studies, 1974-1990." Epidemiology, vol. 11, no. 5, 2000, pp. 589-97.

Full Text PubMed

Wojtasek DA, Teixidor HS, Govoni AF, Gareen IF. "Diagnostic quality of mammograms obtained with a new low-radiation-dose dual-screen and dual-emulsion film combination." American Journal of Roentgenology, vol. 154, no. 2, 1990, pp. 265-70.

Full Text PubMed

DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M. "Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors." The American Journal of Surgical Pathology, vol. 14, no. 1, 1990, pp. 12-23.

Full Text PubMed

Staiano-Coico L, Wong R, Ngoi SS, Jacobson I, Morrissey KP, Lesser ML, Gareen IF, McMahon C, Cennerazzo W, DeCosse JJ. "DNA content of rectal scrapings from individuals at low and high risk for the development of colorectal cancer. A feasibility study." Cancer, vol. 64, no. 12, 1989, pp. 2579-84.

Full Text PubMed

Research

Research Overview

Dr. Gareen focuses on cancer screening trials. She is interested in the downstream consequences of screening, including medical care utilization, iatrogenic consequences, changes in quality of life, and the impact of screening and screening results on smoking cessation.

Dr. Gareen also focuses on potential biases arising in cancer screening trials.

Research Statement

Dr. Gareen has been involved with the American College of Radiology Imaging Network (ACRIN) since its inception. As part of ACRIN, she has worked on the National Lung Cancer Screening Trial, the National Colonography Screening Trial, and the National Oncologic PET Registry. She is now a member of the merged ECOG-ACRIN Clinical Research Group.

Funded Research

Ilana F. Gareen, PI, National Cancer Institute, Lung Screening: Efficacy versus Effectiveness: The goal of this project is to compare the efficacy of lung screening in community practice with that reported in the National Lung Screening Trial (NLST) with respect to the rate and type of abnormalities suspicious for lung cancer, the rate and type of significant incidental findings that are seen on lung screening and may be clinically important, but that are not related to lung cancer, and the diagnostic testing that is done to evaluate lung and other abnormalities. (R01 CA215240), 01/17/2018 – 12/31/2024 (NCE), $3,038,662
Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Network Group Statistics and Data Management Center: This subcontract covers support for the operations of Brown office of the Statistics and Data Management Center (SDMC) of ECOG-ACRIN Cancer Research Group. (Statistical Core subaward #1800006) (U10 CA180794), 04/29/2014 – 02/28/2025, $9,254,000
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN Tomosynthesis Mammographic Imaging Screen Trial: (TMIST): The project lead and team will assist with the oversight and implementation of TMIST, (UG1 CA189828-06-BRWN3), 08/01/2017 – 07/31/2025, $10,290,710
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base: This project involves organizing and operating a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies in Cancer Care Delivery Research (CCDR). – CCDR (UG1 CA189828-06-BRWN2), 08/01/2014 – 07/31/2025, $1,410,414
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base: This project involves organizing and operating a Biostatistics Core in collaboration with the Biostatistics Center at the Dana Farber Cancer Institute. The work of the Biostatistics Core will be part of the ECOG-ACRIN proposed research program comprising studies covering cancer prevention, control, and screening. – CT (UG1 CA189828-06-BRWN1), 08/01/2014 – 07/31/2025, $1,414,745
Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, ACR, Imaging Dementia - Evidence for Amyloid Scanning Study: A Study to Improve Precision in Amyloid PET Coverage and Patient Care: The Center for Statistical Sciences (CSS), Brown University will be responsible for overseeing all data collection, review and analysis efforts associated with the New IDEAS Study, 07/01/2020 – 12/31/2027, $892,982
Bradley Zebrack, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Cancer Survivors: The proposed study intends to identify and define functional genomic pathways through which psychosocial and social environmental risk and resilience factors influence gene regulation in AYAs, and thus contribute to a greater understanding of health disparities in post-treatment survivorship (1R01 CA261752), 09/01/2021 – 08/31/2026, $1,110,813
Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving medication adherence using a CONnected CUstomized Treatment Platform (CONCURxP): This project intends to test an mHealth intervention to improve Palbociclib adherence by conducting a randomized controlled trial (RCT) of a CONnected CUstomized Treatment Platform (CONCURxP) vs. enhanced usual care. (1R01 CA262312-01A1), 08/01/22 – 07/31/27, $955,099
Galareh Sadigh, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer patients: Our goals are to (1) assess intervention effectiveness, by comparing proportions of patients in the enhanced usual care and CostCOM intervention who develop behavioral, psychosocial and material financial hardship and experience “sticker shock” and/or surprise billing at 12 months; (2) To assess the short-term psychological effect of OOP cost communication independent from the combined effect with financial navigation; (3) To assess the moderator effect of financial self-efficacy on intervention effectiveness between two groups; (4) To explore the processes of implementation and dissemination (accuracy of OOP cost estimates, satisfaction with care, acceptability, adoption, appropriateness, fidelity, penetration/reach, and sustainability) of our intervention at community oncology sites. (R01 CA272680), 12/01/22 – 11/30/27, $908,658
Lynne Wagner, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Randomized controlled trial of FoRtitude: Targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors in community oncology settings,: This study addresses the recently identified need for accessible CBT-based interventions by both developing and deploying a user-centered eHealth intervention, as well as establishing feasibility through a multi-site collaboration with three NCI Community Oncology Research Program (NCORP) Sites. This study implements randomized controlled trial (RCT), 07/01/2024-06/30/29, $697,936.
Dominique Michaud, PI, Ilana F. Gareen, Co-I, National Institutes of Health, Using DNA methylation array data to improve risk stratification and identification of lung cancers in the National Lung Screening Trial. (R01 CA280815), 08/20/23—3/31/2027, $408,278.
John Salsman PI, Ilana F. Gareen, Co-I, Addressing financial hardship in adolescent and young adult cancer survivors: Efficacy and implementation of a multilevel intervention in community-based oncology practices: The goal of this project is to conduct a mixed-methods study in order to elucidate multi-level predictors of financial hardship and provide a robust evidence-base for future financial interventions among young adult cancer survivors, (R01CA282653-01A1),07/01/2024-06/30/29, $900,585.
Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, ACR, The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), The Center for Statistical Sciences (CSS), Brown University will be responsible for monitoring and reporting progress in Alz-Net participant accrual and data collection, reviewing data completeness and quality, planning and implementing data analyses, collaborating in the development of reports and manuscripts, and addressing methodologic issue arising in Alz-Net. The Alz-Net statistical team has experience in clinical trials and observational studies of chronic disease, including Alzheimer’s Dementia, and also expertise in linking registry data with data from health care providers and health insurance in the public and private sectors, 01/01/2023 – 12/31/2029, $2,062,048.
Joseph Sparano PI, Ilana F. Gareen Co-I, Breast Cancer Research Program (BCRP), Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), Dept. of the Army – USAMRAA, TAILORx-RxPONDER Clinical Research Extension Award: Advancing Progress, Precision, and Equity in Breast Cancer Care: Upon completion of this project, it is expected that the 21-gene RS and SET Index will be used in combination to guide use of adjuvant chemotherapy use with greater precision that currently possible with the RS alone, sparing additional patients unneeded chemotherapy, and identifying some who would derive a large chemotherapy benefit but otherwise would not have been advised to receive chemotherapy based on the RS results alone, (BC221354), 09/2023 – 08/2027, $39,657.

Completed Grants

Ilana F Gareen, PI, National Cancer Institute, Outcomes Associated with Significant Incidental Findings in Lung Cancer Screening (R01 CA204222), 03/17/2017 – 02/28/2023 (NCE), $1,254,419
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (Patient-Reported Outcomes Component: PRO) (UG1 CA189828-06-BRWN-EA2185-PCyst), 10/01/2019 –07/31/2023, $1,500,000
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (Cost-Effectiveness Analysis Component: CEA) (UG1 CA189828-06-BRWN-EA2185-CEA), 10/01/2019 –07/31/2023, $1,500,000
Elyse Park, PI, Ilana F. Gareen, Co-PI, National Cancer Institute, Implementing a Virtual Tobacco Treatment in Community Oncology Practices (R01 CA214427), 02/01/2018 – 07/31/2023, $247,172
John Salsman, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN NCORP Trial (UG1CA189828), 08/01/2020 – 07/31/2022, $347,246
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Developing an Analytic Resource for Efficiently Linking EA Participants to Medicare data to identify patients with Alzheimer's disease and its related dementias (DAREtoLEAP) (3UG1 CA189828-08S1), 08/01/2021 – 07/31/2022, $296,089
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – COVID19 Supplement (5UG1CA189828-07S3), 08/01/2020 – 07/31/2022, $88,727
Robert Gray, PI, Ilana F. Gareen, Co-I, National Cancer Institute, Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability in ECOG-ACRIN Studies (U01 CA233169), 09/01/2018 – 08/31/2023, $191,656
Bonnie Ky, PI, Ilana F. Green, Co-I, National Heart, Lung, and Blood Institute, Planning Grant for CARISMA – Cancer Therapy Risk-reduction with Intensive Systolic BP Management (R34 HL146927), 08/01/2019 – 07/31/2022, $283,385
Constantine Gatsonis, PI, Ilana F. Gareen, Co-I, American College of Radiology, Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study, 06/01/15 – 12/31/20, $3,217,134
Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers’ Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning, 09/15/17 – 05/31/21, $690,943
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – CT (PCyst), 10/01/2019 – 07/31/2027, $3,299,994
Apgar, Ilana F. Gareen, Co-I, ACR Foundation, EA1141 Abbreviated MRI Study, 09/16/21 – 08/31/21, $53,021
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – EASEE PRO, 08/01/18 – 07/31/19, $19,947
Ilana F. Gareen, PI, NCI-NHGRI, NCI-NHGRI Precision Medicine Ancillary Studies – COMET, 03/01/17 – 02/28/18, $79,413
Vincent Mor, PI, Ilana F. Gareen, Co-I, National Institute of Aging, Caregivers' Reactions and Experience: Imaging Dementia Evidence for Amyloid Scanning CARE IDEAS, 08/01/16 – 7/31/17, $1,373,989
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, National Cancer Institute, ECOG-ACRIN NCORP Research Base – Incorporating the C-TUQ among NCTN and NCORP Clinical Trial Participants, 08/01/16 – 07/31/17, $80,694
Fenghai Duan, PI, Ilana F. Gareen, Co-I, Blue Earth Diagnostics, Blue Earth Diagnostics Multi-Center Trial of FACBC, 08/01/16 – 07/31/19, $61,097
Fenghai Duan/Ilana F. Gareen (MPIs), World Molecular Imaging Society, NOPR NaF CMS Collaboration, 01/01/17 – 12/31/17, $136,698
Mitchell Schnall, PI, Ilana F. Gareen, Co-I, Agency for Healthcare Research and Quality, ACRIN NLST Follow-Up, 0301/16 – 02/28/17, $15,000
Ilana F. Gareen PI, American College of Radiology, ACRIN Protocol 7151 Statistical Support, 04/01/11 – 12/31/15, total awarded $268,000.
Constantine Gatsonis/ Mitchell Schnall MPI, Ilana F. Gareen Co-I, National Cancer Institute, NCI/ECOG-ACRIN NCORP Research Base-CT (1UG1CA189828-01-BRWN1) 08/01/14 – 07/31/16, total awarded $410,072.
Constantine Gatsonis/ Mitchell Schnall (MPIs) , Ilana F. Gareen Co-I, NCI/ECOG-ACRIN NCORP Research Base - CCDR, National Cancer Institute (1UG1CA189828-01-BRWN2), 08/01/14 – 07/31/16, total awarded $312,044.
Constantine Gatsonis PI, Ilana F. Gareen Co-I, ACR Foundation, RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/13-09/29/15, total awarded $317,926.
Constantine Gatsonis/ Ilana F. Gareen (MPIs), National Cancer Institute, Biostatistics Data Management Center for ACRIN National Lung Screening Trial Supplement ( U10 CA79778), 07/01/02 - 12/31/14, total awarded $23,442,291.
Constantine Gatsonis PI, Ilana F. Gareen Co-I National Cancer Institute, Biostatistics Data Management Center for ACRIN (U10 CA79778), 03/01/99-12/31/14, total awarded $17,951,912.
Constantine Gatsonis PI, Ilana F. Gareen Co-I, Agency for Healthcare Research, RESCUE: Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive Examinations, 09/30/10-09/29/13, total awarded $2,071,559.
Anna Tosteson PI, Constantine Gatsonis/Ilana F. Gareen Co-Sub PI, National Cancer Institute, Grand Opportunity Grant: Comparative Effectiveness of Advanced Imaging in Cancer, National Cancer Institute, RC2 CA148259, Subcontract to Dartmouth University, 09/30/09-05/31/13, total awarded $2,071,559.
Constantine Gatsonis PI, Ilana F. Gareen Co-I Investigator, Academy of Molecular Imaging, National Oncologic PET Registry (NOPR), [PI: Gatsonis], 05/01/06-12/31/13, total awarded $1,207,017.
Constantine Gatsonis PI , Ilana F. Gareen Co-I, Patient Centered Outcomes Research Institute, Standards in the Design, Conduct, and Evaluation of Research Evaluating Diagnostic Testing Strategies for Patient Centered Outcomes, 01/04/12-06/15/12, total awarded $77,868.
Ilana F. Gareen PI, National Cancer Institute, Compliance with Lung Cancer Screening, National Cancer Institute (R03 CA 139584), 06/01/09-05/31/12, total awarded $149,895.
Constantine Gatsonis, Ilana F. Gareen Co-I, National Cancer Institute, Biostatistics Data Management Center for Computerized Tomographic Colonography Trial (CTC) (5U01 CA 079778-09), 01/01/05-12/31/09, total awarded $1,244,061.
Constantine Gatsonis, Ilana F. Gareen Co-I National Cancer Institute/American College of Radiology Subcontract Co-Investigator, ACRIN Fellowship (CA94032), 01/01/03-08/31/05, total awarded $160,552.

Background

Education and Training

Year	Degree	Institution
1997	PhD	University of California, Los Angeles
1985	MPH	Yale University

Honors and Awards

American College of Radiology Imaging Network Outstanding Contribution Award 2008.

American College of Radiology Imaging Network Outstanding Contribution Award 2002.

Pew Health Policy Fellow, RAND/University of California, Los Angeles, 1989-1992.

Affiliations Visualize it

Collaborators

Name	Title
Gatsonis, Constantine	Henry Ledyard Goddard University Professor of Statistical Sciences, Director of the Center for Statistical Sciences
Gutman, Roee	Professor of Biostatistics

Researchers@Brown

Researchers@Brown

Ilana F Gareen

Associate Professor of Epidemiology (Research)

Overview

Brown Affiliations

Research Areas

Publications Visualize it

Research

Research Overview

Research Statement

Funded Research

Background

Education and Training

Honors and Awards

Affiliations Visualize it

Collaborators

Teaching

Teaching Overview

Teaching